The new HCPCS Level II code for “Injection, tocilizumab-aazg (Tyenne), biosimilar, 1 mg” is Q5135. “These CMS designations are important reimbursement milestones for Tyenne because they ease access ...

LAKE ZURICH, Ill., April 09, 2026--(BUSINESS WIRE)--Fresenius Kabi, a part of Fresenius, and a leading provider of essential medicines and medical technologies, announced today that the Centers for ...

On July 2, 2024, Fresenius Kabi (“Fresenius”) announced the immediate availability of TYENNE (tocilizumab-aazg), in a subcutaneous formulation, in the United States. TYENNE, a biosimilar to ACTEMRA ...

Please provide your email address to receive an email when new articles are posted on . Tyenne (tocilizumab-aazg) is available in a prefilled syringe, pen injector or vial. The biosimilar will launch ...

Credit: Fresenius Kabi. Tyenne is now available as a 20mg/mL single-dose vial (80mg/4mL, 200mg/10mL, or 400mg/20mL) for further dilution prior to IV infusion. The biosimilar received FDA approval on ...

Tyenne is the first tocilizumab biosimilar by Fresenius Kabi, an operating company of Fresenius SE, with an intravenous and subcutaneous formulation approved by the FDA. The tocilizumab biosimilar ...

LAKE ZURICH, Ill.--(BUSINESS WIRE)--Fresenius Kabi, an operating company of Fresenius, announced today that the Centers for Medicare and Medicaid Services (CMS) issued a permanent, product-specific ...

Fresenius Kabi, a part of Fresenius, and a leading provider of essential medicines and medical technologies, announced today that the Centers for Medicare & Medicaid Services has issued ...

LAKE ZURICH, Ill., October 29, 2024--(BUSINESS WIRE)--Fresenius Kabi, an operating company of Fresenius, announced today that the Centers for Medicare and Medicaid Services (CMS) issued a permanent, ...

For TYENNE subcutaneous injection, advise patients to seek immediate medical attention if they experience any symptoms of a hypersensitivity reaction. If anaphylaxis or other hypersensitivity reaction ...